# Glucocorticoids do not cause a clinically relevant elevation in the urine protein-to-creatinine ratio in dogs with inflammatory protein-losing enteropathy

**Authors:** Cameron J. Wood, Peter S. Chapman, Cara Horowitz

PMC · DOI: 10.3389/fvets.2025.1751769 · Frontiers in Veterinary Science · 2026-01-23

## TL;DR

This study found that glucocorticoid treatment in dogs with inflammatory protein-losing enteropathy does not cause significant increases in urine protein levels.

## Contribution

The study shows glucocorticoids do not clinically elevate urine protein-to-creatinine ratio in iPLE dogs.

## Key findings

- The median urine protein-to-creatinine ratio increased slightly but remained below 0.9 in all dogs.
- CCECAI scores decreased significantly after treatment, indicating improved clinical status.
- UPC correlated with CCECAI at baseline but not at follow-up.

## Abstract

This study aimed to document changes in the urine protein-to-creatinine ratio (UPC) in dogs with inflammatory protein-losing enteropathy (iPLE) undergoing glucocorticoid therapy and with no overt evidence of concurrent renal disease.

Dogs with histologically confirmed iPLE, a serum albumin level of <2.0 g/dL, gastrointestinal signs for ≥2 weeks, and no recent glucocorticoid use were prospectively enrolled at any of the four referral centers between 24 December 2020 and 25 May 2023. Dogs with azotemia, hepatopathy, urinary sediment abnormalities, or confirmed intestinal parasites were excluded. All dogs received prednisone or prednisolone (1 mg/kg BID), clopidogrel, and a new hypoallergenic or low-fat diet. Repeat urinalysis, UPC measurement, urine culture, blood pressure measurement, and serum chemistry analysis were performed after 1–2 weeks (T1) and 2–3 months (T2). Canine chronic enteropathy clinical activity index (CCECAI) scores were assessed at T0 and T1 for correlation with UPC.

Twelve dogs with iPLE were enrolled. Eight dogs were excluded due to comorbidities, loss to follow-up, or euthanasia. The median UPC increased from baseline (0.10) to T1 (0.25) and T2 (0.30). No dog had a UPC of >0.9. Mean CCECAI scores decreased from baseline (8.75) to T1 (3.08). UPC correlated with CCECAI at baseline [ρ (95%CI) 0.71 (0.22–0.91)], but not at follow-up [T1: ρ (95%CI) 0.04 (−0.55–0.60)] or changed from T0 to T1 [ρ (95%CI) 0.15 (−0.67–0.46)].

Glucocorticoids increase the UPC in dogs with iPLE to the same extent as has previously been shown in healthy dogs.

Clinically significant proteinuria in iPLE dogs treated with glucocorticoids should prompt clinicians to consider alternative etiologies.

## Linked entities

- **Chemicals:** prednisone (PubChem CID 5865), prednisolone (PubChem CID 5755), clopidogrel (PubChem CID 2806)
- **Species:** Canis lupus familiaris (taxon 9615)

## Full-text entities

- **Genes:** ALB (albumin) [NCBI Gene 403550] {aka CSA}
- **Diseases:** azotemia (MESH:D053099), proteinuria (MESH:D011507), iPLE (MESH:D011504), hepatopathy (MESH:D020754), renal disease (MESH:D007674), gastrointestinal (MESH:D005767), chronic enteropathy (MESH:D002908)
- **Chemicals:** creatinine (MESH:D003404), prednisolone (MESH:D011239), prednisone (MESH:D011241), clopidogrel (MESH:D000077144)
- **Species:** Canis lupus familiaris (dog, subspecies) [taxon 9615]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12875912/full.md

## References

19 references — full list in the complete paper: https://tomesphere.com/paper/PMC12875912/full.md

---
Source: https://tomesphere.com/paper/PMC12875912